Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00628199
First received: February 22, 2008
Last updated: February 20, 2009
Last verified: February 2009
  Purpose

This is a research study in which your cells will be used for somatic cell nuclear transfer (SCNT), and/or genetic reprogramming research which may result in the production of stem cell lines. This study does not provide treatment.


Condition Intervention
Metabolic Diseases
Infertility
Procedure: Improving the scientific process of human cell reprogramming

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Derivation of Primary Donor Cell Lines for Human Cell Reprogramming

Resource links provided by NLM:


Further study details as provided by Stanford University:

Estimated Enrollment: 60
Study Start Date: September 2007
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Detailed Description:

It is thought that studies of genetic reprogramming and SCNT using human cells have the potential to give us new basic knowledge about human development. Current work will focus on developing this basic knowledge. In the future, human embryonic stem cell lines (hESC) derived from genetic reprogramming and SCNT may also have the potential to develop into cell types that are useful for cell-based therapies to treat human disease and disability.

  Eligibility

Ages Eligible for Study:   1 Year to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:1. Donors with a degenerative disease phenotype or genetic disorders such as Type I Diabetes, heart disease, or infertility (azoospermia and premature ovarian failure)

Exclusion Criteria:1. Unable to read or understand English. 2. Unable to provide skin biopsy sample due to skin condition in the underarm area.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00628199

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Renee A. Reijo Pera Stanford University
  More Information

No publications provided

Responsible Party: Tasha Kalista, M.A.
ClinicalTrials.gov Identifier: NCT00628199     History of Changes
Obsolete Identifiers: NCT00553826
Other Study ID Numbers: SU-12202007-950
Study First Received: February 22, 2008
Last Updated: February 20, 2009
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Infertility
Metabolic Diseases
Genital Diseases, Male
Genital Diseases, Female

ClinicalTrials.gov processed this record on September 14, 2014